October 24, 2024

FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’s

 FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’s

FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’s

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.

Pam Belluck